

-2023-

1. Time-series transcriptome analysis of peripheral blood mononuclear cells obtained from individuals who received the SARS-CoV-2 mRNA vaccine. Watanabe Y, et al. *J Med Virol* 95(6):e28884. June 2023

-2022-

1. A survey of clinical physician's perceptions of stigma and advocacy in patients with type 2 diabetes in Kanagawa, Japan. Matsuzawa Y, et al. *J Diabetes Investig* 2022; 13: 2073–2080
2. The Proportion of Long-term Response to Anti-N IgG Antibody after 12 Months for COVID-19 Subclinical Infections and a Longitudinal Survey for COVID-19 Subclinical Infections in 2021. *Intern Med.* 2022 Oct 15;61(20):3053-3062
3. Heterogeneity assessment of vaccine-induced effects using point-of-care surrogate neutralization test for severe acute respiratory syndrome coronavirus 2. Watanabe Y. et al. *J Clin Lab Anal.* 2022 Jul;36(7):e24545
4. Study on Continuation of Antibody Prevalence Six Months after Detection of Subclinical Severe Acute Respiratory Syndrome Coronavirus 2 Infections. *Intern Med.* 2022 Jan 15;61(2):159-165
5. Multinational Observational Study to Understand Insulin Treatment Intensification: Japanese Subgroup Analysis of the MOSAIC Study. *Diabetes Ther.* 2022 Feb;13(2):265-274

-2021-

1. Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection. Miyakawa K. et al. *Open Forum Infect Dis.* 2021 Dec 10;9(2):ofab626
2. Effects of 1-year treatment with canagliflozin on body composition and total body water in patients with type 2 diabetes. *Diabetes Obes Metab.* 2021 Dec;23(12):2614-2622

3. Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors. Goto A. et al. *Front Microbiol.* 2021 May 7;12:661187

-2020-

1. Survey of the current status of subclinical coronavirus disease 2019 (COVID-19) : *Journal of Infection and Chemotherapy*, 26(2020):1294-1300, December 2020
2. Validation of Analysis Models on Relocation Behavior of Molten Core Materials in Sodium-Cooled Fast Reactors Based on the Melt Discharge Experiment : *International Conference on Nuclear Engineering (ICONE)* : conference paper, August 2020
3. Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study : *Journal of Diabetes Investigation*, March 2020
4. Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study : *Diabetes Technology & Therapeutics*, 22(3) · Feb. 2020

-2019-

1. Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-Study: *Journal of Clinical Medicine Research*, 11(5):311-320 · May 2019
2. Sitagliptin Versus Ipragliflozin for Type 2 Diabetes in Clinical Practice : *Journal of Endocrinology and Metabolism*, 9(5):151-158 · January 2019

-2018-

1. Effects of a novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate (K-877), on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance : *Journal of Diabetes Investigation*, 9(6) · March 2018

-2017-

1. Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus. Kawata T, et al. *J Clin Med Res.* 2017 Jul; 9(7): 586–595

2. Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes.:Yuasa S, et al. J Clin Med Res. 2017 Mar; 9(3): 188–192

-2016-

1. Cross-National Variation in Glycemic Control and Diabetes-Related Distress Among East Asian Patients Using Insulin: Results from the MOSAIC Study.:Matsuba I, et al. Diabetes Ther. 2016Jun; 7(2): 349–360
2. Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.:Yuasa S, et al. J Clin Med Res. 2016 Jun; 8(6): 461–471
3. Factors Influencing Changes in Hemoglobin A1c and Body Weight During Treatment of Type 2 Diabetes With Ipragliflozin: Interim Analysis of the ASSIGN-K Study.Iemitsu K, et al. J Clin Med Res. 2016May; 8(5): 373–378
4. Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.Iizuka T, et al. J Clin Med Res. 2016 Mar; 8(3): 267.
5. Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.Takeda H, et al. J Clin Med Res. 2016 Feb; 8(2): 130–140.
6. Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study.Iizuka T, et al. J Clin Med Res. 2016 Feb; 8(2): 116–125.

-2015-

1. Geographic patterns in patient demographics and insulin use in 18 countries a global perspective from the multinational observational study assessing insulin use: understanding the challenges associated with progression of therapy (MOSAIC).Polinski JM, et al. BMC Endocr Disord. 2015; 15: 46.

2. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study. Umezawa S, et al. *BMC Endocr Disord.* 2015; 15: 34.
3. Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study. Ishikawa M, et al. *J Clin Med Res.* 2015 Aug; 7(8): 607–612.
4. Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes. Maeda H, et al. *Diabetes Res Clin Pract.* 2015 Jun 108, e35-e76

-2014-

1. Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. Kubota A, et al. *J Diabetes Investig.* 2014 Jul; 5(4): 445–448.
2. Is a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients? Kawata T, et al. *J Clin Med Res.* 2014 Apr; 6(2): 138–144.
3. Safety and efficacy of adding sitagliptin to insulin in patients with type 2 diabetes: the ASSIST-K study. Takai M, et al. *Diabetes Res Clin Pract.* 2014 Mar 103, e1-e56

-2013-

1. Effect of Caloric Intake 25 or 30 kcal/kg/day on the Glycemic Control in Obese Patients With Type 2 Diabetes. Masuda K, et al. *J Clin Med Res.* 2013 Oct; 5(5): 368–375
2. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longer. Kanamori A, et al. *J Clin Med Res.* 2013 Jun; 5(3): 217–221

-2012-

1. Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients. Kubota A, et al. *J Diabetes Investig.* 2012 Dec 20; 3(6): 503–509

2. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. Kubota A, et al. *J Clin Med Res*. 2012 Oct; 4(5): 309–313
3. Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross-sectional survey of 15,652 patients. Arai K, et al. *J Diabetes Investig*. 2012 Aug 20; 3(4): 396–401.
4. Fasting insulin levels and metabolic risk factors in type 2 diabetic patients at the first visit in Japan: a 10-year, nationwide, observational study (JDDM 28). Matsuba I, et al. *Diabetes Care*. 2012 Sep; 35(9): 1853–1857.
5. Cross-sectional survey of diabetic neuropathy in Kanagawa and clinical significance of a touch test using tissue paper. Jin Y, et al. *J Diabetes Investig*. 2012 Jun 6; 3(3): 252–258.
6. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23). Oishi M, et al. *J Int Med Res*. 2012, 40, Issue 2
7. The current status of blood pressure control among patients with hypertension: a survey of actual clinical practice. Hatori N, et al. *J Nippon Med Sch*. 2012, 79, 69-78
8. Optimal Combination of Effective ANti-hypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan. Kageyama S, et al. *Hypertens Res*. 2012, 35, 221-227
9. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Maeda H, et al. *Diabetes Res Clin Pract*. 2012, Jan, 95(Issue 1), e1-e26

1. Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus. Kubota A, et al. *J Diabetes Investig.* 2011, Oct 7; 2(5): 377–380.

-2010-

1. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients. Arai K, et al. *Endocr J.* 2010, 57(6),499-507

-2009-

1. The status of glycemic control by general practitioners and specialists for diabetes in Japan: a cross-sectional survey of 15,652 patients with diabetes mellitus. Arai K, et al. *Diabetes Res Clin Pract.* 2009, Mar 83(Issue 3), 289-402

-1997-

1. Matsuba I. :Life guidance and family planning for diabetic patient and family members: *Nippon Rinsho.* 1997 Nov;55 Suppl:402-7. Review. Japanese.

-1995-

1. Tsuruoka A, Matsuba I, Toyota T, Isshiki G, Nagataki S, Ikeda Y. :Antibodies to GAD in Japanese diabetic patients: a multicenter study. :*Diabetes Res Clin Pract.* 1995 Jun;28(3):191-9.

-1990-

1. Matsuba I, Ikeda Y. :Life guidance and family planning for diabetic patient and family members :*Nippon Rinsho.* 1990 Dec;48 Suppl:842-7. Japanese.
2. Matsuba I, Lernmark A. :A novel microwell indirect immunofluorescence assay to detect antibodies against islet cell surface antigens in insulin-dependent diabetes mellitus. :*Reg Immunol.* 1990 Jan-Feb;3(1):23-8.

-1988-

1. Matsuba I, Lernmark A, Madsen O, Michelsen B, Nielsen JH, Scholler J, Vissing H, Welinder B, Tommerup N, Mikkelsen M, et al. :Gene probes to detect cross-culture contamination in hormone producing cell lines. :*In Vitro Cell Dev Biol.* 1988 Nov;24(11):1071-6.

-1987-

1. Matsuba I, Marner B, Nerup J, Lernmark A. :Detection of islet cell autoantibodies in newly diagnosed diabetic patients using insulin-producing Syrian hamster cells. :Diabetes Res. 1987 Mar;4(3):103-7.

-1986-

1. Mori Y, Suko M, Okudaira H, Matsuba I, Tsuruoka A, Sasaki A, Yokoyama H, Tanase T, Shida T, Nishimura M, et al. :Preventive effects of cyclosporin on diabetes in NOD mice. :Diabetologia. 1986 Apr;29(4):244-7.

-1985-

1. Marner B, Lernmark A, Ludvigsson J, MacKay P, Matsuba I, Nerup J, Rabinovitch A. :Islet cell antibodies in insulin-dependent (type 1) diabetic children treated with plasmapheresis. :Diabetes Res. 1985 Sep;2(5):231-6.

-1984-

1. Tanese T, Narimiya M, Yamada H, Matsuba I, Tsuruoka A, Sasaki K, Mori Y, Ishii K, Ikeda Y, Abe M. :The effect of methyleneblue on insulin and glucagon release stimulated by glucose and arginine in the isolated perfused rat pancreas :Nippon Naibunpi Gakkai Zasshi. 1984 Jun 20;60(6):729-37. Japanese.
2. Maruyama T, Takei I, Matsuba I, Tsuruoka A, Taniyama M, Ikeda Y, Kataoka K, Abe M, Matsuki S. :Cell-mediated cytotoxic islet cell surface antibodies to human pancreatic beta cells. :Diabetologia. 1984 Jan;26(1):30-3.

-1983-

1. Tanese T, Narimiya M, Yamada H, Matsuba I, Sasaki T, Tsuruoka A, Ishi K, Utsunomiya K, Ikeda Y, Abe M. :Hyperglycemia and inhibition of glucose-induced insulin release in 6-aminonicotinamide treated rats :Nippon Naibunpi Gakkai Zasshi. 1983 Nov 20;59(11):1752-8. Japanese.

-1982-

1. Narimiya M, Yamada H, Matsuba I, Ikeda YU, Tanese T, Abe M. :The effect of hypoxia on insulin and glucagon secretion in the perfused pancreas of the rat. :Endocrinology. 1982 Sep;111(3):1010-4.

2. Matsuba I, Tanese T, Abe M. :Human pancreatic islet cell clones secreting insulin, glucagon and somatostatin: immunocytochemical and functional studies. :Arch Histol Jpn. 1982 Feb;45(1):111-9.

-1981-

1. Narimiya M, Yamada H, Matsuba I, Ikeda Y, Tanese T, Abe M. :Adrenergic modulation of insulin and glucagon secretion from the isolated perfused rat pancreas. :Endocrinol Jpn. 1981 Jun;28(3):281-92.